1. Multicentric validation of indigenous molecular test Truenat™ MTB for detection of Mycobacterium tuberculosis in sputum samples from presumptive pulmonary tuberculosis patients in comparison with reference standards
- Author
-
N S Gomathi, Anant Mohan, T Kannan, Raman R. Gangakhedkar, Devendra Singh Chauhan, Bindu Dey, Rohit Sarin, Manjula Singh, Jyoti M. Logani, Srikanth Tripathy, Soumya Swaminathan, M V V Rao, Jiten Singh Khangembam, Anuj Bhatnagar, V.P. Myneedu, and Urvashi B. Singh
- Subjects
medicine.medical_specialty ,Tuberculosis ,India ,lcsh:Medicine ,Truenat ,Sensitivity and Specificity ,General Biochemistry, Genetics and Molecular Biology ,law.invention ,Mycobacterium tuberculosis ,Pulmonary tuberculosis ,law ,Internal medicine ,medicine ,Nucleic Acid Amplification Tests ,Humans ,Tuberculosis, Pulmonary ,Polymerase chain reaction ,rapid detection of MTB ,biology ,business.industry ,lcsh:R ,Sputum ,battery-operated tuberculosis detection kit - molecular detection - mtb - poc test - rapid detection of mtb - truenat - tuberculosis ,General Medicine ,Gold standard (test) ,Reference Standards ,medicine.disease ,biology.organism_classification ,molecular detection ,Battery-operated tuberculosis detection kit ,tuberculosis ,MTB ,Original Article ,Leprosy ,medicine.symptom ,business ,POC test - Abstract
Background & objectives: Early case detection is essential to interrupt transmission and to prevent further spread of tuberculosis (TB) in high endemic settings. Nucleic acid amplification tests (NAATs) with visual read-outs are ideal as point-of-care tests. Truenat™ MTB is an indigenous chip-based NAAT for detection of Mycobacterium tuberculosis, which involves extraction of DNA and real-time polymerase chain reaction (PCR) using portable, automated, battery-operated instruments. The current multicentric study was aimed to evaluate Truenat for detection of MTB in sputum samples obtained from patients with presumptive pulmonary TB with reference to culture as gold standard and Xpert as a comparator. Methods: The study was conducted at four sites, namely ICMR-National Institute for Research in Tuberculosis, Chennai; All India Institute of Medical Sciences, New Delhi; ICMR-National JALMA Institute for Leprosy and Other Mycobacterial Diseases, Agra; and National Institute of TB and Respiratory Diseases, New Delhi. Patients suspected to have TB were screened for eligibility. Two sputum samples were collected from each patient. Tests included smear, Xpert and Truenat directly from the sputum sample and culture by Lowenstein-Jensen (L-J) medium and MGIT960 from decontaminated pellets. Sample used for Truenat assay was coded. Resolution of Truenat false positives was done using an in-house PCR with TRC4 primers. Results: The study enrolled 2419 presumptive TB patients after screening 2465 patients, and 3541 sputum samples were collected from the enrolled patients. Results of 2623 samples were available for analysis. Truenat showed a positivity rate of 48.5 per cent as compared to 37.0 per cent by Xpert. The sensitivities of Truenat and Xpert were was 88.3 and 79.7 per cent, respectively in comparison with culture. Interpretation & conclusions: Truenat MTB identified more positives among culture-confirmed samples than Xpert and had higher sensitivity. In addition, other advantageous operational features of Truenat MTB were identified which would be useful in field settings.
- Published
- 2020